Biotechnology – The News Desk

26Dec

By adminNo Comments

Money

How to Ride the Biotech Roller Coaster

With stocks starting to price in interest-rate cuts next year, the biotech sector has emerged as a winner for investors seeking riskier bets with more distant payoffs.But investing in this industry is tricky because biotech is a sector of haves and have-nots. While every industry has its winners and losers, the gap in biotech is bigger due to the binary nature of drug development. Many companies spend years testing one medical approach or platform. In the end, either the idea works or it doesn’t, and that could be the difference between tripling your investment or losing it all. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

13Dec

By adminNo Comments

Money

It’s Biotech Stocks’ Time to Shine

These are hard times for the biotech sector. Barely a day goes by without layoffs being announced somewhere in Boston or California, and there are still more than 100 biotech stocks worth less than the cash they have in the bank.Yet there are also very clear signs that the worst might be over for the sector. For investors with a long-term horizon, a recent rally leaves plenty of room for further gains.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

27Oct

By adminNo Comments

World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1351 ET – Venture-capital investment in biotechnology startups continues to slide from its 2021 peak, but that isn’t a reason to think innovation will suffer, says Kevin Eisele, managing director, equity capital markets for investment bank William Blair. As biotech investment surged from 2018 to 2021, many similar companies emerged to pursue the same drug targets, he says. Now fewer quick-follower companies attract attention as investors target more-differentiated companies. Moreover, investment in healthcare venture-capital funds remains robust. U.S. healthcare VCs had raised $13.7 billion as of midyear, putting 2023 on pace to nearly match the record $2...

This $5 Billion Biotech Home Run Took Less Than a Year

25Oct

By adminNo Comments

Money

This $5 Billion Biotech Home Run Took Less Than a Year

You can’t completely blame Pfizer’s executives, yet Roche’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look.In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer. (The Wall Street Journal had reported the talks back in July). Big pharma companies focused on the drug industry equivalent of free agent signings will often overlook one of their own hot prospects. In fact, Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharma’s trash can be another company’s treasure. But this one became an almost instant All-Star.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c...

Danaher: Danaher beats profit estimates on respiratory testing demand

24Oct

By adminNo Comments

Business

Danaher: Danaher beats profit estimates on respiratory testing demand

Danaher on Tuesday beat Wall Street estimates for third-quarter profit as strong demand for its diagnostic tests for respiratory diseases helped soften the blow from weaker sales at the healthcare conglomerate's life-sciences unit. The diagnostics unit, which makes kits, also used for COVID-19 testing, as well as reagents and other tools, reported sales of $2.25 billion, beating the average analyst estimate of $2.12 billion, according to LSEG data. However, the life sciences unit, which provides reagents and lab equipment used in the discovery of new drugs and vaccines, posted sales of $1.71 billion, missing estimates of $1.78 billion. "Revenue in the third quarter came in ahead of our expectations, with Biotechnology performing as anticipated, and higher respiratory testing revenue more ...

24Oct

By adminNo Comments

World

This $5 Billion Biotech Home Run Took Less Than a Year

You can’t completely blame Pfizer’s executives, yet Roche’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look.In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer. (The Wall Street Journal had reported the talks back in July). Big pharma companies focused on the drug industry equivalent of free agent signings will often overlook one of their own hot prospects. In fact, Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharma’s trash can be another company’s treasure. But this one became an almost instant All-Star.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c...

The Brash Strategy That Made Vivek Ramaswamy a Fortune

9Sep

By adminNo Comments

World

The Brash Strategy That Made Vivek Ramaswamy a Fortune

Updated Sept. 9, 2023 10:51 am ETVivek Ramaswamy was a novice biotech entrepreneur in 2016 with no advanced medical training and no record of developing drugs. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8